DOCICAR: Cardiac Dysfunction in Cirrhosis

This study has been completed.

Sponsored by:	Hvidovre University Hospital
Information provided by:	Hvidovre University Hospital
ClinicalTrials.gov Identifier:	NCT00250315

Purpose

Patients with cirrhosis have a altered cardiac response to stress. This study evaluate the cardiac response by MRI during dobutamine stress. Hypothesis: impared increase in cardiac output, cardiac index, ejection fraction.

Condition	Intervention	Phase
Cirrhosis Cirrhotic Cardiomyopathy	Drug: Dobutamine	Phase III

MedlinePlus related topics: Cardiomyopathy Cirrhosis

Drug Information available for: Dobutamine Dobutamine hydrochloride Dobutamine lactobionate Dobutamine tartrate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Cardiac Dysfunction in Cirrhosis: Cirrhotic Cardiomyopathy Evaluated by Dobutamin MRI.

Further study details as provided by Hvidovre University Hospital:

Study Start Date:	November 2005
Study Completion Date:	October 2007

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Non alkoholic cirrhosis

Exclusion Criteria:

Coma hepaticum
Primary cardiac diseases

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00250315

Locations

Denmark, Hvidovre
Hvidovre University Hospital
Copenhagen, Hvidovre, Denmark, 2650

Sponsors and Collaborators

Hvidovre University Hospital

Investigators

Study Director:

Søren Møller, DrMsci, MD

Hvidovre University Hospital

More Information

Study ID Numbers:	(KF) 01 270675
Study First Received:	November 4, 2005
Last Updated:	October 31, 2007
ClinicalTrials.gov Identifier:	NCT00250315
Health Authority:	Denmark: Sundhedsstyrelsen

Study placed in the following topic categories:

Liver Diseases
Heart Diseases
Digestive System Diseases
Fibrosis

Liver Cirrhosis
Cardiomyopathies
Dobutamine

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-Agonists
Adrenergic Agents
Cardiotonic Agents
Sympathomimetics
Physiological Effects of Drugs
Cardiovascular Agents

Protective Agents
Pharmacologic Actions
Adrenergic Agonists
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Cardiovascular Diseases
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on January 16, 2009